<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02128971</url>
  </required_header>
  <id_info>
    <org_study_id>AM-FEB-INDO-2013-01</org_study_id>
    <nct_id>NCT02128971</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo</brief_title>
  <official_title>A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sprim Advanced Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the gastrointestinal (GI) tolerability of 5 different&#xD;
      iron supplements (Ferrochel®, Sumalate®,ferrous fumarate, ferrous sulfate and ferric&#xD;
      glycinate) at the same dose (90mg) and placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia, the most common disorder of blood, is characterized by a decrease in number of red&#xD;
      blood cells (RBCs) or less than normal quantity of hemoglobin in blood.Hemoglobin is an&#xD;
      oxygen-carrying protein inside RBCs that transports oxygen from the respiratory organs to the&#xD;
      rest of body. Several vitamins, minerals and nutrients are required for the development and&#xD;
      production of RBCs, such as vitamin B12, folic acid and iron. Iron is an essential component&#xD;
      of hemoglobin. Iron deficiency accounts for half of the anemia cases worldwide, and iron&#xD;
      deficiency anemia is the most common nutritional disorder in the world.Iron deficiency can be&#xD;
      the result of inadequate intake in the diet, poor absorption, the extra needs during growth&#xD;
      or pregnancy, and blood loss. Thus, children and women are at highest risk.&#xD;
&#xD;
      Full blood count and hemoglobin measurements are used to diagnose anemia, and measurement of&#xD;
      serum ferritin level (cutoff of 12-15 mg/l) is considered as the best single and non-invasive&#xD;
      test for the diagnosis of iron-deficiency. Treatment of anemia depends on the cause and the&#xD;
      severity. Oral iron supplement is the simplest and most cost-effective option to treat anemia&#xD;
      and replenish body storage.&#xD;
&#xD;
      The objective of this clinical trial is to compare the gastrointestinal (GI) tolerability of&#xD;
      5 different iron supplements (Ferrochel®, Sumalate®,ferrous fumarate, ferrous sulfate and&#xD;
      ferric glycinate) at the same dose (90mg)and placebo. The primary objective is to compare the&#xD;
      gastrointestinal tolerability of the above quoted products through:&#xD;
&#xD;
        -  Self-assessment questionnaires - Gastrointestinal Symptoms Questionnaire5&#xD;
&#xD;
        -  Self reported diaries&#xD;
&#xD;
      The Secondary objective of the study is to assess the change from baseline of the parameters&#xD;
      below:&#xD;
&#xD;
        -  Hemoglobin level&#xD;
&#xD;
        -  Hematocrit level&#xD;
&#xD;
        -  Ferritin level&#xD;
&#xD;
      This prospective clinical trial is a single-center, six-arms, randomized, double-blinded,&#xD;
      parallel study. Subject will be screened according to inclusion exclusion criteria, and blood&#xD;
      sample will be collected to ensure the hemoglobin and ferritin levels. Subject also will be&#xD;
      asked to complete the Gastrointestinal Symptoms Questionnaire. The study product will be&#xD;
      administered 30 days, orally once daily in the morning after breakfast. The study plan as&#xD;
      follow:&#xD;
&#xD;
      Visit 1: Screening / Baseline (day -7)&#xD;
&#xD;
        1. Protocol information will be given by the investigator to potential subjects. Each&#xD;
           participant will sign a consent form that further explains what is entailed by&#xD;
           participating in the study as well as providing subjects with information on how to&#xD;
           report any adverse events (AEs) that may arise.&#xD;
&#xD;
        2. Collection of demographic information and medical history.&#xD;
&#xD;
        3. A 10-mL blood sample will be collected by venipuncture for lab analysis of hemoglobin&#xD;
           and ferritin.&#xD;
&#xD;
        4. Subjects will complete the Gastrointestinal Symptoms Questionnaire for baseline record.&#xD;
&#xD;
        5. Subjects that meet the inclusion and exclusion criteria will be scheduled for visit 2&#xD;
&#xD;
      Visit 2: Day 0&#xD;
&#xD;
        1. PI or designee will assign an unique subject ID number to each eligible subject in&#xD;
           ascending order; the subject ID corresponds to an assigned investigational product code&#xD;
           on the subject list and to the label on the investigational product (IP) given to the&#xD;
           subject.&#xD;
&#xD;
        2. Subjects will complete the Gastrointestinal Symptoms Questionnaire.&#xD;
&#xD;
        3. A 10-ml blood sample will be collected by venipuncture for lab analysis of hemoglobin,&#xD;
           ferritin and hematocrit.&#xD;
&#xD;
        4. Subject diary will be dispensed.&#xD;
&#xD;
        5. The PI or designee will dispense the investigational product capsules to subjects,&#xD;
           according to the subject list provided. Each subject will receive sufficient&#xD;
           investigational product capsules to last for 30 days.&#xD;
&#xD;
        6. Subjects will begin to consume the investigational product capsule once a day, at the&#xD;
           same time after breakfast, for 30 days starting on Day 1.&#xD;
&#xD;
      Visit 3: Day 15 Window period ± 2 days will be allowed for this visit&#xD;
&#xD;
        1. A 10-ml blood sample will be collected by venipuncture for lab analysis of hemoglobin,&#xD;
           ferritin and hematocrit.&#xD;
&#xD;
        2. Subjects will bring their unused IP to the study site. Compliance will be monitored by&#xD;
           counting the remaining investigational product capsules. The remaining IP capsules will&#xD;
           then be returned to the subject.&#xD;
&#xD;
        3. Subjects will complete the Gastrointestinal Symptoms Questionnaire.&#xD;
&#xD;
        4. Subject's diary will be collected and new diary will be dispensed.&#xD;
&#xD;
      Visit 4: Day 30 Window period ± 2 days will be allowed for this visit&#xD;
&#xD;
        1. A 10-mlblood sample will be collected by venipuncture for lab analysis of hemoglobin,&#xD;
           ferritin and hematocrit.&#xD;
&#xD;
        2. The PI or designee will collect any remaining investigational product. Compliance will&#xD;
           be monitored by counting the remaining investigational product capsules.&#xD;
&#xD;
        3. Subjects will complete the Gastrointestinal Symptoms Questionnaire.&#xD;
&#xD;
        4. Subject's diary will be collected.&#xD;
&#xD;
        5. New Subject diary will be dispensed.&#xD;
&#xD;
      Visit 5: Day 37 Window period ± 2 days will be allowed for this visit&#xD;
&#xD;
        1. Subjects will complete the Gastrointestinal Symptoms Questionnaire.&#xD;
&#xD;
        2. Subject diaries will be collected.&#xD;
&#xD;
      Adverse Event and Serious Adverse Event will be recorded since the subjects begin consuming&#xD;
      the investigational product and throughout the study. SAE should be recorded in the SAE form&#xD;
      and reported to Sponsor or CRA within 24 hours. All SAE will be reported to Ethic Committee&#xD;
      and Regulatory Authority.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal questionnaire to measure the gastrointestinal tolerability</measure>
    <time_frame>change from baseline in Gastrointestinal questionnaire on 7 days after the last dose of 30 days investigational product consumption</time_frame>
    <description>The gastrointestinal tolerability of the products will be assessed by self-assessment questionnaires and self-reported diaries at baseline (screening), day 0, day 15, day 30 of investigational product consumption, and 7 days after finished the investigational product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the laboratory result to measure the change from baseline</measure>
    <time_frame>up to 30 days of investigational product consumption</time_frame>
    <description>hemoglobin levels of each subject will be measured at baseline (screening), day 0, day 15 and day 30 of investigational product consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the laboratory result to measure the change from baseline</measure>
    <time_frame>up to 30 days of investigational product consumption</time_frame>
    <description>Hematocrit levels of each subject will be measured at baseline (screening), day 0, day 15 and day 30 of investigational product consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the laboratory result to measure the change from baseline</measure>
    <time_frame>up to 30 days of investigational product consumption</time_frame>
    <description>Ferritin levels of each subject will be measured at baseline (screening), day 0, day 15 and day 30 of investigational product consumption</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Ferrochel® 90 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrochel® capsule 90 mg OD for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sumalate® 90 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sumalate® capsule 90 mg OD for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferrous Fumarate 90 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous Fumarate capsule 90 mg OD for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferrous Sulfate 90 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous Sulfate capsule 90 mg OD for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferric glycinate 90 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferric glycinate capsule 90 mg OD for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo capsule OD for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ferrochel® 90 mg</intervention_name>
    <description>Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days</description>
    <arm_group_label>Ferrochel® 90 mg</arm_group_label>
    <other_name>Ferrous Bisglycinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sumalate® 90 mg</intervention_name>
    <description>Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days</description>
    <arm_group_label>Sumalate® 90 mg</arm_group_label>
    <other_name>Ferrous aspartoglycinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ferrous fumarate 90 mg</intervention_name>
    <description>Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days</description>
    <arm_group_label>Ferrous Fumarate 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ferrous Sulfate 90 mg</intervention_name>
    <description>Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days</description>
    <arm_group_label>Ferrous Sulfate 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ferric Glycinate 90 mg</intervention_name>
    <description>Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days</description>
    <arm_group_label>Ferric glycinate 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women, 18-50 years of age, inclusive&#xD;
&#xD;
          2. Hemoglobin 8 g/dl - 11 g/dl&#xD;
&#xD;
          3. Ferritin levels &lt; 20 mcg/l (20 ng/mL)&#xD;
&#xD;
          4. Subject, or subject's acceptable representative, has voluntarily signed and dated an&#xD;
             informed consent form, approved by a local Ethics Committee/Institutional Review Board&#xD;
             prior to any participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating&#xD;
&#xD;
          2. Amenorrhea&#xD;
&#xD;
          3. Severe anemia (hemoglobin 7 g/dl) or other blood abnormality (e.g., leukopenia,&#xD;
             thrombocytopenia, polycythemia vera)&#xD;
&#xD;
          4. Serious illness that may confound study results or interfere with compliance&#xD;
&#xD;
          5. Subjects that have followed specific diet, eg. high protein diet, within 30 days prior&#xD;
             to study start&#xD;
&#xD;
          6. Subjects that have taken iron supplements within 30 days prior to study start&#xD;
&#xD;
          7. Subjects that are allergic to any of the ingredients in the products&#xD;
&#xD;
          8. Participation in other clinical trials within three months prior to screening&#xD;
&#xD;
          9. Known intolerance to oral iron supplements&#xD;
&#xD;
         10. Habitual smokers (more than 3 cigarettes per week)&#xD;
&#xD;
         11. Other medical conditions that, in the investigator's opinion, may confound study&#xD;
             results or prelude the subject's ability to safely complete the trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yahdiana Harahap, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory Faculty of Pharmacy, Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eka Windari Rusman</last_name>
    <phone>+62 21 83701201</phone>
    <email>eka.windari@sprim.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Hartle</last_name>
    <phone>8017734631</phone>
    <email>jhartle@albionminerals.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratory Faculty of Pharmacy, Universitas Indonesia</name>
      <address>
        <city>Depok</city>
        <state>West Java</state>
        <zip>16424</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yahdiana Harahap, Professor</last_name>
      <phone>+62-21-7270031</phone>
      <email>yahdiana.ms@ui.ac.id</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>April 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <last_update_submitted>May 5, 2014</last_update_submitted>
  <last_update_submitted_qc>May 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron supplement study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrous fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

